

A sequential RCM/fragmentation protocol towards chiral, stereodefined medium ring sesquiterpenoids. A carvone route to *E*- and *Z*-germacrenes

Goverdhan Mehta* and R. Senthil Kumaran

Department of Organic Chemistry, Indian Institute of Science, Bangalore 560012, India


Received 29 August 2005; revised 11 October 2005; accepted 19 October 2005

Available online 7 November 2005

Abstract—A short, flexible and enantioselective approach towards 10-membered germacratrienones, from the commercially available monoterpene chiron (–)-carvone, involving RCM and Grob-type fragmentation as the pivotal steps is delineated.
© 2005 Elsevier Ltd. All rights reserved.

Among sesquiterpenoid natural products, the monocyclic germacranes, embodying a 10-membered medium ring skeleton **1** occupy a special position in view of their widespread occurrence and their role as biosynthetic progenitors of several polycyclic frameworks.¹ Notable examples of germacranes natural products are the biogenetically important sesquiterpenoid hedycaryol **2**,^{2a} biologically active 1,6-germacradien-5-ol **3**^{2b} and a prototypical germacranolide represented by costunolide **4**.^{2c} An interesting structural feature of germacranes natural products is the presence of either *E,E*- (as in **2** and **4**) or *E,Z*- (as in **5**)^{2d} or somewhat rare *Z,Z*- (as in **6**)^{2e} configuration of the double bonds in the 10-membered ring. There are also examples of germacranes like sielbodianine A **7**^{2f} wherein only one double bond, generally in the *E*-configuration, is present.


For reasons of structural diversity and historical importance, germacranes natural products have attracted^{3,4a–d} and continue to engage considerable attention^{4e–i} from the synthetic chemistry community. Several interesting strategies³ have been devised for accessing the 10-membered ring of these natural products with appropriate positioning and stereocontrol of the olefinic bonds. We delineate here a new approach to germacranes from the readily available monoterpene chiron *R*-(–)-carvone by tactically sequencing ring-closing metathesis (RCM) and C–C bond fragmentation on appropriately crafted




decalinic platforms to generate a 10-membered cyclic alkene.⁵ Since, Grob-type heterolytic fragmentations are under tight stereocontrol (the central C–C bond undergoing cleavage is antiperiplanar to the electrofuge and nucleofuge groups),⁶ the substrates can be programmed to deliver either an *E*- or *Z*-cyclodecene thereby rendering this approach both flexible and stereoselective. It is the relative stereochemical positioning of the electrofuge and the nucleofuge on the (–)-carvone derived eudesmane platforms that has enabled access to *E*- or *Z*-germacrenes through fragmentation protocols and it is the execution of this strategy that forms the main thrust of this letter.

* Corresponding author. Tel.: +91 8022 932850; fax: +91 8023 600936; e-mail: gm@orgchem.iisc.ernet.in

Recently, we described⁷ the elaboration of *R*(-)-carvone **8** to diastereomeric aldol products **9** and **10** in preparatively useful yields, through the intermediacy of an α,β -epoxy ketone as shown in Scheme 1. The substrates **9** and **10** appeared very well suited for executing the contemplated RCM-fragmentation protocol to access 10-membered germacranes. In this context, it was considered more prudent to implement an initial model study. Addition of the Grignard reagent derived from allyl chloride to the β -hydroxy aldol product **9** was stereoselective, directed by the chelating interactions on the axial face, due to the presence of the β -hydroxy group, and gave the diallylated compound **11** in very good yield, Scheme 2.⁸ A RCM reaction on **11** using the Grubbs' first generation catalyst⁹ proceeded in excellent yield to give bicyclic 1,3-*cis*-diol **12**, its stereochemistry being secured through an X-ray crystal structure determination.¹⁰ While acquisition of the 1,3-diol moiety (as in **12**) was a good omen, their *trans* relationship was a



Scheme 1. Reagents and conditions: (a) 30% H_2O_2 , 6 N NaOH , MeOH , 0 °C, 92%; (b) Li , liq. NH_3 , $\text{CH}_2=\text{CHCH}_2\text{Br}$, Et_2O , -78 °C, 60%.




Scheme 2. Reagents and conditions: (a) 2.5 equiv $\text{CH}_2=\text{CHCH}_2\text{MgCl}$, THF , -78 °C, 90%; (b) 5 mol% Grubbs' catalyst, C_6H_6 , 80 °C, 94%; (c) PCC , DCM , rt, 71%; (d) NaBH_4 , MeOH , 0 °C, **12** (54%) and **14** (35%) in a ratio of 3:2; (e) MsCl , Et_3N , DMAP , DCM , 0 °C, 92%; (f) NaH , C_6H_6 , 65 °C, 79%.


pre-requisite for the orchestration of a fragmentation protocol and mandated an inversion of the C9 β -hydroxy stereochemistry in **12**. As the Mitsunobu-like inversion protocols on the C9 hydroxyl group in **12** were unsuccessful, it was oxidized to the hydroxy-ketone **13** and further reduced with NaBH_4 to furnish a mixture (2:3) of the desired *trans*-1,3-diol **14** and **12**, Scheme 2. The *trans*-diol **14** was readily converted to the mesylate **15** and its activation with base induced smooth fragmentation to furnish *Z,Z*-nor-germacratrienone **16**⁸ in good yield, Scheme 2.

With the successful acquisition of **16**, implementation of the RCM-fragmentation sequence in the α -hydroxy aldol product **10** was undertaken next. Addition of the allyl Grignard reagent to **10** was moderately stereoselective (6:1) and in the absence of the directive influence of the axial hydroxyl group (cf. **9**) furnished the *cis*-1,3-diol **17**⁸ as the major product with favoured addition from the axial face, Scheme 3. A RCM reaction in **17** with Grubbs' catalyst proceeded uneventfully and led to the bicyclic *cis*-diol **18**. Once again, implementation of the fragmentation reaction required a *trans*-disposition of the 1,3-diol moiety to ensure antiperiplanar geometry.⁶ Subsequently, **18** was oxidized to the hydroxy-ketone **19** and reduced with LiAlH_4 to furnish a mixture (1:2) of *trans*-1,3-diol **20** and **18**, Scheme 3. Mesylation of **20** led to **21** and subsequent exposure to NaH resulted in fragmentation to the *E,Z*-nor-germacratrienone **22**,⁸ Scheme 3.¹¹


Enthused by the success in accessing the nor-germacratrienones **16** and **22**, we ventured to extend our studies towards the complete C_{15} skeleton of the germacranes. Addition of the Grignard reagent derived from 3-chloro-1-butene to the β -hydroxy-ketone **9** in the presence of Ce^{+3} furnished two diastereomeric addition products **23** and **24** (α - and β -methyl isomers, 55:45) as reported previously, Scheme 4.⁷ Both, **23** and **24** were formed through stereoselective addition of the Grignard reagent to **9** from the equatorial face (vide supra) and further elaborated to *Z,Z*-germacratrienones as described below.




Scheme 3. Reagents and conditions: (a) 2.5 equiv $\text{CH}_2=\text{CHCH}_2\text{MgCl}$, THF , -78 °C, 93%; (b) 10 mol% Grubbs' catalyst, C_6H_6 , 80 °C, 78%; (c) PCC , DCM , rt, 75%; (d) LAH , THF , 0 °C, **18** (55%) and **20** (27%) in a ratio of 2:1; (e) MsCl , Et_3N , DMAP , DCM , 0 °C, 90%; (f) NaH , C_6H_6 , 65 °C, 67%.



Scheme 4. Reagents and conditions: (a) anhyd CeCl_3 , 2.5 equiv $\text{CH}_2=\text{CHCH}(\text{CH}_3)\text{MgCl}$, THF, -78°C , 95%.




Scheme 7. Reagents and conditions: (a) MsCl , Et_3N , DMAP, DCM, 0°C , 95%; (b) NaH , C_6H_6 , 65°C , 60%.




Scheme 5. Reagents and conditions: (a) 8 mol % Grubbs' catalyst, C_6H_6 , 80°C , 92%; (b) PCC, DCM, rt, 80%; (c) NaBH_4 , MeOH, 0°C , **25** (51%) and **27** (34%) in a ratio of 1.5:1; (d) MsCl , Et_3N , DMAP, DCM, 0°C , 90%; (e) NaH , C_6H_6 , 65°C , 62%.

A RCM reaction on **23** was efficient and led to the eudesmane derivative **25**, Scheme 5. The *cis*-1,3-diol moiety in **25** was modified to set up the fragmentation by oxidation to the hydroxy-ketone **26** and reduction to epimeric alcohols **25** and **27** (1.5:1). The *trans*-1,3-diol **27** was converted to the mesylate **28** and careful exposure to NaH in the complete absence of moisture and air led to the fragmented product *Z,Z*-germacatrienone **29**, Scheme 5.^{8,12} An identical sequence starting from the diastereomer **24** involved RCM to the bicyclic eudesmane derivative **30**, PCC oxidation to **31** and NaBH_4 reduction to obtain the *trans*-1,3-diol **32** as a minor product along with **30** (1:4), Scheme 6. The mesylate **33** resulting from **32**, on exposure to NaH under a rigorous moisture and air free regime, led to the diastereomeric *Z,Z*-germacatrienone **34**, Scheme 6.^{8,12}



Scheme 6. Reagents and conditions: (a) 5 mol % Grubbs' catalyst, C_6H_6 , 80°C , 89%; (b) PCC, DCM, rt, 78%; (c) NaBH_4 , MeOH, 0°C , **30** (72%) and **32** (18%) in a ratio of 4:1; (d) MsCl , Et_3N , DMAP, DCM, 0°C , 80%; (e) NaH , C_6H_6 , 65°C , 70%.



Scheme 8. Reagents and conditions: (a) MsCl , Et_3N , DMAP, DCM, 0°C , 92%; (b) NaH , C_6H_6 , 65°C , 62%.

To further amplify the potential of our RCM/fragmentation based strategy to access stereochemically diverse *E*- and/or *Z*-configured germacrenes, we also implemented the fragmentation protocols on the *trans*-1,3-diols **35** and **36**, obtained from the α -hydroxy aldol product **10** (vide supra) following the steps outlined for the diastereomeric product **9**, Schemes 7 and 8.

Thus **35** was converted into its mesylate **37** and treatment with NaH led to the fragmented *E,Z*-germacatrienone **38**, Scheme 7.^{8,11} Similarly, the *trans*-1,3-diol **36** was derivatized to its mesylate **39** and base mediated fragmentation led to the *E,Z*-germacatrienone **40**, Scheme 8.^{8,11}

In summary, we have outlined a short and versatile approach to germacatrienes based on sequential RCM and fragmentation protocols from the readily available monoterpene chiron (–)-carvone. By manipulating the precursor *trans*-1,3-diol moiety on the eudesmane platform into different stereochemical settings, it was possible to generate either *E*- or *Z*-alkene in the 10-membered ring in a predictable manner.


Acknowledgements

This work was supported by the Chemical Biology Unit of JNCASR at the Indian Institute of Science. One of us (R.S.K.) thanks CSIR for the award of a Research Fellowship. G.M. is a CSIR Bhatnagar Fellow.


References and notes

- (a) Connolly, J. D.; Hill, R. A. *Dictionary of Terpenoids. In Mono- and Sesquiterpenoids*; Chapman & Hall: London, 1991; Vol. 1, pp 214–285; (b) Herz, W. *Israel J. Chem.* **1977**, *16*, 32–44.
- (a) Southwell, I. A. *Phytochemistry* **1970**, *9*, 2243–2245; (b) Bohlmann, F.; Knoll, K.-H.; Zdero, C.; Mahanta, P.; Grenz, M.; Suwita, A.; Ehlers, D.; Van, N. L.; Abraham, W.-R.; Natu, A. A. *Phytochemistry* **1977**, *16*, 965–985; (c) Rao, A. S.; Kelkar, G. R.; Bhattacharya, S. C. *Tetrahedron* **1960**, *9*, 275–283; (d) Bardón, A.; Cardona, L.;


- Cartagena, E.; Catalán, C. A. N.; Pedro, J. R. *Phytochemistry* **2001**, *57*, 125–130; (e) de Gutierrez, A. N.; Bardón, A.; Catalán, C. A. N.; Gedris, T. B.; Herz, W. *Biochem. Syst. Ecol.* **2001**, *29*, 633–647; (f) Ruzicka, L. *Bull. Soc. Chim. Belg.* **1932**, *41*, 565.
- For a review on the synthesis of germacrane sesquiterpenes, see: Minnard, A. J.; Wijnberg, J. B. P. A.; de Groot, A. *Tetrahedron* **1999**, *55*, 2115–2146.
 - Selected examples of syntheses of germacrane: (a) Corey, E. J.; Hortmann, A. G. *J. Am. Chem. Soc.* **1965**, *87*, 5736–5742; (b) Iguchi, M.; Nishiyama, A.; Yamamura, S.; Hirata, Y. *Tetrahedron Lett.* **1969**, *10*, 4295–4298; (c) Wharton, P. S.; Sundin, C. E.; Johnson, D. W.; Klunder, H. C. *J. Org. Chem.* **1972**, *37*, 34–38; (d) Still, W. C. *J. Am. Chem. Soc.* **1977**, *99*, 4186–4187; (e) Minnard, A. J.; Wijnberg, J. B. P. A.; de Groot, A. *Tetrahedron* **1994**, *50*, 4755–4764; (f) Minnard, A. J.; Wijnberg, J. B. P. A.; de Groot, A. *J. Org. Chem.* **1997**, *62*, 7336–7345; (g) Nevalainen, M.; Koskinen, A. M. P. *J. Org. Chem.* **2002**, *67*, 1554–1560; (h) Smitt, O.; Hogberg, H.-E. *Synlett* **2002**, 1273–1276; (i) Ivkovic, A.; Matovic, R.; Saicic, R. N. *Org. Lett.* **2004**, *6*, 1221–1224.
 - Grob-like C–C bond fragmentation⁶ of decalinic systems to generate 10-membered rings and its application to the synthesis of germacrane has been observed previously.^{3,4b,c,e,i} Ref. 4i, reporting a RCM/fragmentation route to a natural product periplanone C appeared while the present work was nearing completion.
 - (a) Grob, C. A.; Schiess, P. W. *Angew. Chem., Int. Ed. Engl.* **1967**, *6*, 1–106; (b) Grob, C. A. *Angew. Chem., Int. Ed. Engl.* **1969**, *8*, 535–622; (c) Sternbach, D.; Shibuya, M.; Jaisli, F.; Bonetti, M.; Eschenmoser, A. *Angew. Chem., Int. Ed. Engl.* **1979**, *18*, 634–636; (d) Fehr, C.; Galindo, J.; Etter, O.; Thommen, W. *Angew. Chem., Int. Ed.* **2002**, *41*, 4523–4526.
 - Mehta, G.; Kumaran, R. S. *Tetrahedron Lett.* **2003**, *44*, 7055–7059.
 - All new compounds were characterized on the basis of IR, ¹H and ¹³C NMR and HRMS data. Spectral data for selected compounds: (–)-**16**: [α]_D²⁴ –170.4 (*c* 1.2, CHCl₃); IR 1702 cm^{–1}; ¹H NMR (300 MHz, CDCl₃): δ 5.88 (ddt, *J* = 10.5, 5.7, 1.8 Hz, 1H), 5.62–5.54 (m, 1H), 5.04 (t, *J* = 8.4 Hz, 1H), 4.75 (s, 1H), 4.53 (s, 1H), 3.13 (td, *J* = 5.4, 2.1 Hz, 1H), 3.09–3.00 (m, 2H), 2.86 (dd, *J* = 13.8, 10.2 Hz, 1H), 2.73 (m, 1H), 2.52 (dd, *J* = 14.1, 5.4 Hz, 1H), 2.25–2.19 (m, 2H), 2.06 (dd, *J* = 15.0, 2.4 Hz, 1H), 1.78 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 211.8, 147.2, 135.4, 130.7, 122.4, 121.8, 109.7, 44.1, 41.2, 39.8, 31.3, 28.5, 23.6, 22.4; HRMS (ES): *m/z* calcd for C₁₄H₂₀ONa (M+Na): 227.1412; found: 227.1427. Compound (+)-**22**: [α]_D²⁴ (+)–6.0 (*c* 1.0, CHCl₃); IR 1704 cm^{–1}; ¹³C NMR (75 MHz, CDCl₃): δ 210.2, 148.7, 133.0, 130.0, 129.7, 122.2, 109.4, 48.2, 47.5, 43.0, 39.4, 34.0, 21.1, 18.2; HRMS (ES): *m/z* calcd for C₁₄H₂₀ONa (M+Na): 227.1412; found: 227.1418. Compound (–)-**29**: [α]_D²³ –20.0 (*c* 0.8, CHCl₃); IR 1701 cm^{–1}; ¹H NMR (300 MHz, CDCl₃): δ 5.78 (ddt, *J* = 10.8, 5.4, 2.1 Hz, 1H), 5.34 (dd, *J* = 10.8, 5.4 Hz, 1H), 5.04 (t, *J* = 8.4 Hz, 1H), 4.76 (s, 1H), 4.51 (s, 1H), 3.35–3.26 (m, 1H), 3.08 (dd, *J* = 15.3, 12.0 Hz, 1H), 2.97 (dd, *J* = 13.5, 11.4 Hz, 1H), 2.74–2.66 (m, 1H), 2.38–2.22 (m, 2H), 2.14 (t, *J* = 6.0 Hz, 1H), 2.03 (dd, *J* = 15.3, 1.8 Hz, 1H), 1.78 (s, 6H), 1.23 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 215.2, 147.3, 135.4, 130.4, 128.9, 121.5, 109.8, 47.8, 40.9, 37.4, 31.8, 28.1, 23.6, 22.5, 18.8; HRMS (ES): *m/z* calcd for C₁₅H₂₂ONa (M+Na): 241.1568; found: 241.1568. Compound (–)-**34**: [α]_D²³ –326.7 (*c* 1.0, CHCl₃); IR 1705 cm^{–1}; ¹H NMR (300 MHz, CDCl₃): δ 5.72 (dd, *J* = 17.4, 10.2 Hz, 1H), 5.57 (t, *J* = 10.2 Hz, 1H), 5.06 (t, *J* = 8.4 Hz, 1H), 4.75 (s, 1H), 4.56 (s, 1H), 3.17 (qui, *J* = 6.9 Hz, 1H), 2.98 (dd, *J* = 15.9, 11.1 Hz, 1H), 2.70–2.54 (m, 3H), 2.32–2.26 (m, 3H), 1.79 (s, 3H), 1.77 (s, 3H), 1.15 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 211.9, 147.3, 135.9, 130.4, 127.3, 121.4, 109.6, 47.1 (2C), 40.1, 31.1, 28.0, 23.2, 22.7, 15.7; HRMS (ES): *m/z* calcd for C₁₅H₂₂ONa (M+Na): 241.1568; found: 241.1580. Compound (–)-**38**: [α]_D²³ –23.2 (*c* 0.8, CHCl₃); IR 1698 cm^{–1}; ¹³C NMR (100 MHz, CDCl₃): δ 213.5, 148.5, 136.4, 133.9, 129.3, 126.8, 110.0, 46.6, 44.3, 41.2, 40.0, 33.1, 31.3, 20.4, 17.6; HRMS (ES): *m/z* calcd for C₁₅H₂₂ONa (M+Na): 241.1568; found: 241.1584. Compound (+)-**40**: [α]_D²³ +68.2 (*c* 1.1, CHCl₃); IR 1702 cm^{–1}; ¹³C NMR (75 MHz, CDCl₃): δ 214.5, 148.9, 134.1, 130.8, 129.6, 127.9, 109.2, 47.8, 47.0, 46.1, 38.8, 33.8, 21.3, 18.7, 18.5; HRMS (ES): *m/z* calcd for C₁₅H₂₂ONa (M+Na): 241.1568; found: 241.1568.
 - Grubbs, R. H.; Chang, H. *Tetrahedron* **1998**, *54*, 4413–4450.
 - X-ray data for **12**: C₁₄H₂₂O₂, MW = 222.32, colourless crystal, crystal system: orthorhombic, space group: P2₁2₁2₁, cell parameters: *a* = 6.7810(40), *b* = 8.2778(49), *c* = 22.5066(14) Å, *V* = 1263.34(13) Å³, *Z* = 4, ρ_{calcd} = 1.17 g cm^{–3}, *F*(000) = 487.9, μ = 0.076 mm^{–1}, total no. of l.s. parameters = 149, *R*₁ = 0.043 for 1999 reflections with *F*₀ > 4 σ (*F*₀) and 0.047 for all 2147 reflections. *wR*₂ = 0.116, GOF = 0.999, restrained GOF = 0.999 for all data (CCDC 282317).

ORTEP diagram of **12**

- We observed that whenever there was an *E*-double bond present in the germacatrienes, as in **22**, **38** and **40**, considerable line broadening and partial doubling of signals were observed in the ¹H NMR spectra due to the presence of conformational isomers. Recording the spectra even at (–50 °C) did not help much although reversible changes were noticed. On the other hand, the ¹³C NMR spectra were quite clean. Attributing the presence of conformers to the *Z*-disubstituted double bond in the germacatrienes, we also prepared the corresponding germacraenones (iv–vi) from the saturated mesylates (i–iii), respectively. Germacraenones (iv–vi) exhibited clean, clear cut ¹H and ¹³C NMR spectra.



12. When the fragmentation reactions were performed without adequate precautions to avoid oxygen and moisture, the main product from either **28** or **33** was the α -ketol **i**, a product of unusual oxidation at the activated doubly allylic tertiary carbon and its structure was determined by X-ray crystallography.



X-ray data for **vii**: $C_{15}H_{22}O_2$, MW = 234.33, colourless crystal, crystal system: trigonal, space group: $P3_1$, cell parameters: $a = 12.9950(30)$, $c = 7.1599(33)$ Å, $V =$

$1047.10(6)$ Å³, $Z = 3$, $\rho_{\text{calcd}} = 1.04$ g cm⁻³, $F(000) = 360.0$, $\mu = 0.063$ mm⁻¹, total no. of l.s. parameters = 242, $R_1 = 0.038$ for 2526 reflections with $F_0 > 4\sigma(F_0)$ and 0.043 for all 2783 reflections. $wR_2 = 0.091$, GOF = 1.058, restrained GOF = 1.058 for all data (CCDC 282316).

